Amplia Therapeutics: FDA Granted Fast-Track Designation to Amplia's Lead Drug Narmafotinib in Advanced Pancreatic Cancer >ATX.AU

Dow Jones09/20 07:17

FDA FAST TRACK DESIGNATION FOR NARMAFOTINIB IN ADVANCED PANCREATIC CANCER

Yahoo Finance09/20 07:13

Amplia Therapeutics: Advancing Pancreatic Cancer Treatment | ASX:ATX

Proactive Investors08/22 00:49

Amplia Therapeutics Receives Patent for Narmafotinib in Europe, Japan

MT Newswires08/07 10:37

Amplia Therapeutics Shares Rally 17% on Fourth Confirmed Response in Pancreatic Cancer Trial

MT Newswires08/06 10:43

2 ASX Biotech Shares Rocketing More Than 40% on Big News

The Motley Fool07/25 13:15